UpHealth Inc

UPH | $0.3 9.13% 0.0% 350K

(0.0% 1d) (0.0% 1m) (-81.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3.3% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 5,332,649
https://www.gigcapital2.com
Sec Filling | Patents | 2 employees

(United States) GigCapital Global is a Private-to-Public Equity investment group, sponsoring and operating Special Purpose Acquisition Companies ('SPAC', also known as Blank-Check companies). Founded in 2017 by Dr. Avi Katz, the GigCapital Group and its sponsored SPACs are led by an affiliated team of technology industry experts, deploying a unique Mentor-Investors™ methodology to partner with exceptional privately-held and U.S. and non-U.S. public technology companies led by dedicated, innovative entrepreneurs. The GigCapital Group companies offer financial, operational and executive mentoring to U.S. and global private, and non-U.S. public companies, in order to accelerate their path from inception and as a privately-held entity into the growth-stage as a publicly traded company in the U.S. The partnership of the GigCapital Group with these companies continues through an organic and roll-up strategy growth post the transition to a public company.

msa acquisitions spac blank check

add to watch list Paper trade email alert is off

VERDE BIO HOLDINGS, INC.

VBHI | $0.0003 60.0% 400K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (-50.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-46.42% volume)
Earnings Calendar:
Market Cap: $ 623,580
https://www.verdebh.com/
Sec Filling | Patents | 1 employees

(US)

add to watch list Paper trade email alert is off

iSpecimen Inc

ISPC | $0.34 17.93% 14.96% 1.8M

Professional, Scientific, and T...

(0.0% 1d) (35.3% 1m) (-79.9% 1y) (0.0% 2d) (0.0% 3d) (61.9% 7d) (-35.12% volume)
Earnings Calendar: 2024-02-21
Market Cap: $ 3,187,393

Sec Filling | Patents | 75 employees

headquartered in lexington, ma, ispecimen is the marketplace for human biospecimens, providing researchers with the specimens they need from the patients they want. the privately held company has developed the ispecimen marketplace, an online platform connecting healthcare organizations that have access to patients and specimens with the scientists who need them. proprietary, cloud-based technology enables researchers to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. researchers easily and compliantly gain access to specimens to drive scientific discovery. partner sites gain an opportunity to contribute to biomedical discovery as well as their bottom line. and ultimately, healthcare advances for all.

add to watch list Paper trade email alert is off

Werewolf Therapeutics Inc

HOWL | $6.09 3.22% 2.96% 240K

Professional, Scientific, and T...

(0.0% 1d) (1.3% 1m) (159.1% 1y) (0.0% 2d) (0.0% 3d) (4.3% 7d) (99.64% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 263,985,441
https://werewolftx.com
Sec Filling | Patents | n/a employees

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors.The company is continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

cancer immunotherapy msa treatment

add to watch list Paper trade email alert is off

Singular Genomics Systems Inc

OMIC | $0.4 1.27% 2.45% 44K

Professional, Scientific, and T...

(0.0% 1d) (-20.8% 1m) (-60.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-63.29% volume)
Earnings Calendar: 2024-03-18
Market Cap: $ 29,634,198
https://singulargenomics.com
Sec Filling | Patents | 138 employees

Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. The Singular Sequencing Engine is the foundational platform technology that forms the basis of Singular Genomics’ products in development and Singular Genomics’ core product tenets: accuracy, speed, flexibility and scale. Singular Genomics’ first integrated solution is targeted at the NGS market and comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the G4 Integrated Solution. A second integrated solution in development comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the PX Integrated Solution. The PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution.

t-cell

add to watch list Paper trade email alert is off

Recursion Pharmaceuticals Inc - Class A

RXRX | $7.6 3.4% 3.35% 3.4M

Professional, Scientific, and T...

(0.0% 1d) (-27.8% 1m) (40.7% 1y) (0.0% 2d) (0.0% 3d) (1.7% 7d) (-1.67% volume)
Earnings Calendar: 2024-02-26
Market Cap: $ 1,726,289,848
https://www.recursionpharma.com
Sec Filling | Patents | n/a employees

Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Central to its mission is the Recursion Operating System, or Recursion OS, that combines an advanced infrastructure layer to generate what Recursion believes is one of the world's largest and fastest-growing proprietary biological and chemical datasets and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that the company uses to explore foundational biology unconstrained by human bias and navigate to new biological insights which may accelerate its programs. biotechnology company scaling more like a technology company.

drug discovery machine learning

add to watch list Paper trade email alert is off

Compass Therapeutics Inc

CMPX | $1.49 1.36% 0.0% 110K

Professional, Scientific, and T...

(0.0% 1d) (-27.3% 1m) (-48.8% 1y) (0.0% 2d) (0.0% 3d) (1.4% 7d) (-54.28% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 205,007,865

Sec Filling | Patents | 26 employees

compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. novel scientific insights are validated and explored deeply inside our labs before compass pursues the best proprietary combinations of therapeutics into human clinical trials. in 2015, compass quietly closed a $120mm series a financing to fund our ambitious plan to build a fully-integrated biopharmaceutical company from the ground up. our investors are among the most sophisticated venture capitalists in the industry who exemplify our philosophy of building long term economic value only by delivering therapeutics with meaningful efficacy beyond

add to watch list Paper trade email alert is off